Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
1.17
-0.04 (-2.89%)
Bozor ochiq: Aug 12, 2026, 3:03 PM EDT
1.21
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Coherus Oncology, Inc., biopharmaceutical kompaniyasi, Qo'shma Shtatlarda saratonni davolash uchun immunoterapiyalarni tadqiq qiladi, ishlab chiqadi va tijoratlashtiradi. Kompaniya Neulasta, uzoq muddat ta'sir qiluvchi granulotsitlarni stimulyatsiya qiluvchi omilning biosimilyari bo'lgan UDENYCA; yangi avlod dasturlashtirilgan o'lim retseptor-1 inhibitori bo'lgan LOQTORZI; va o'simta mikro-muhitida (TME) bemorlarda bosh va bo'yinning yassi hujayrali karsinomasida interleykin IL-27 ga qarshi yo'naltirilgan IgG1 monoklonal antitelosi bo'lgan Casdozokitug ni ishlab chiqadi. Kompaniya shuningdek, bosh va bo'yinning yassi hujayrali karsinomasiga chalingan bemorlarda o'simta mikro-muhitida (TME) Treg hujayralarida yuqori darajada ifodalangan kemokin retseptori bo'lgan, IgG1 monoklonal antitelosi bo'lgan CHS-114 ni ham ishlab chiqadi. U toripalimabni birgalikda ishlab chiqish va tijoratlashtirish uchun Junshi Biosciences bilan hamkorlik kelishuvi; Surface va Adimab LLC bilan kelishuvlar; Bioeq AG va Genentech, Inc. hamda Surface va Vaccinex, Inc. bilan litsenzion kelishuvlar; va Novartis Institutes for Biomedical Research, Inc. va GlaxoSmithKline Intellectual Property No. 4 Limited bilan tashqi litsenzion kelishuvga ega. Kompaniya, shuningdek, saraton bemorlarini davolash uchun ZM0008 bilan LOQTORZIni ishlab chiqish bo'yicha Zumutor Biologics Inc. bilan klinik hamkorlik kelishuviga ega. Kompaniya ilgari Coherus BioSciences, Inc. nomi bilan tanilgan va 2025 yil may oyida Coherus Oncology, Inc. nomini olgan. Kompaniya 2010 yilda tashkil etilgan va Redwood City, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Rosh Dias M.D., MRCP | Chief Medical Officer |
| Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer & Chairman of Scientific Advisory Board |
| Mr. Andy Rittenberg | Chief Legal Officer |
| Mr. Arvind Sood | Chief Strategy & Corporate Affairs Officer |
| Mr. Bryan J. McMichael | Chief Financial Officer |
| Mr. Dennis M. Lanfear | Chairman, President & CEO |
| Mr. Michael Chen | Senior Vice President of Commercial Analytics & Trade |
| Mr. Sameer Goregaoker | Chief Commercial Officer |
| Ms. Carrie Graham | Vice President of Investor Relations & Advocacy |
| Ms. Rebecca Sunshine | Chief Human Resources Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-05 | S-8 | chrs-20260804xs8.htm |
| 2026-08-05 | 8-K | chrs-20260805x8k.htm |
| 2026-06-15 | 8-K | chrs-20260612x8k.htm |
| 2026-06-01 | 8-K | chrs-20260527x8k.htm |
| 2026-05-28 | DEFA14A | chrs-20260528xdefa14a.htm |
| 2026-05-11 | 8-K | chrs-20260511x8k.htm |
| 2026-05-11 | 10-Q | chrs-20260331x10q.htm |
| 2026-05-05 | DEFA14A | tm2613639d1_defa14a.htm |
| 2026-04-20 | DEF 14A | chrs-20260527xdef14a.htm |
| 2026-04-20 | ARS | chrs-20251231xars.pdf |